Akums Drugs and Pharmaceuticals Limited (AKUMS) Price & Analysis

Compare

4 Followers

AKUMS Stock Chart & Stats

₹420.10

₹13.30(2.17%)

At close: Jan 08 4:00 PM EST

₹420.10

₹13.30(2.17%)

Day’s Range― - ―

52-Week Range₹407.40 - ₹620.00

Previous CloseN/A

Volume56.90K

Average Volume (3M)11.50K

Market Cap

₹73.09B

Enterprise Value₹69.63B

Total Cash (Recent Filing)₹16.78B

Total Debt (Recent Filing)₹902.87M

Price to Earnings (P/E)26.2

Beta1.32

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.33

Shares Outstanding157,393,980

10 Day Avg. Volume12,021

30 Day Avg. Volume11,497

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.32

Price to Sales (P/S)1.74

P/FCF Ratio36.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹680.00

Price Target Upside61.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)17.72

Revenue Forecast (FY)₹42.98B

Bulls Say, Bears Say

Bulls Say

Improved Margins & ProfitabilitySustained gross and net margin recovery indicates stronger pricing power or lower input costs and a return to profitable operations. This durable improvement supports internal reinvestment, debt reduction and resilience to cyclical pressure, underpinning free cash flow quality over months.

Strong Cash GenerationRobust OCF and positive FCF growth signal reliable cash conversion from earnings. A 1.38 OCF/net income ratio shows cash quality above accounting profits, providing durable funding for capex, R&D, working capital and further deleveraging without depending on external financing.

Material DeleveragingA near-elimination of financial leverage materially reduces interest burden and refinancing risk, increasing strategic optionality. This stronger balance sheet provides long-term flexibility to invest in capacity, pursue contracts or weather industry shocks over the next several quarters.

Bears Say

Declining EBIT MarginA falling EBIT margin despite higher gross margins suggests rising SG&A or inefficiencies affecting operating leverage. If persistent, this constrains scalability of profits from revenue growth and may pressure net income and free cash generation absent structural cost fixes.

Slowing Revenue GrowthA sharp slowdown in top-line growth reduces the benefit of operating leverage and implies product mix, market share or demand headwinds. Over months, slower revenue expansion makes margin improvements harder to sustain and raises reliance on cost cuts or new product launches.

Limited Investor Communications/eventsAbsence of earnings call detail and notable corporate events reduces transparency into strategy and execution. Over a multi-month horizon this makes it harder for investors to gauge guidance, product pipeline or commercial progress and could mask emerging operational risks.

Akums Drugs and Pharmaceuticals Limited News

Akums Closes Trading Window Ahead of Q3 FY2025 Unaudited Results

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an announcement. Akums Drugs and Pharmaceuticals Limited has...

3M ago

AKUMS

Akums Secures Patent for Innovative GERD Treatment

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has shared an announcement. Akums Drugs and Pharmaceuticals Limited has...

5M ago

AKUMS

Akums Drugs Expands with New Subsidiary in Malta

The latest update is out from Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ). Akums Drugs and Pharmaceuticals...

5M ago

AKUMS

Akums Expands with New Joint Venture in Zambia

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an update. Akums Drugs and Pharmaceuticals Limited has...

5M ago

AKUMS

AKUMS FAQ

What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?

Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹407.40 and its highest was ₹620.00 in the past 12 months.

What is Akums Drugs and Pharmaceuticals Limited’s market cap?

Akums Drugs and Pharmaceuticals Limited’s market cap is ₹73.09B.

When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?

Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Jun 01, 2026 which is in 75 days.

How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?

Akums Drugs and Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹4.332 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.332.

Is Akums Drugs and Pharmaceuticals Limited overvalued?

According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akums Drugs and Pharmaceuticals Limited pay dividends?

Akums Drugs and Pharmaceuticals Limited does not currently pay dividends.

What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?

Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?

Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.

What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?

Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹4.332 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.789%.

Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:AKUMS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.

Akums Drugs and Pharmaceuticals Limited (AKUMS) Earnings & Revenues

Historic Earnings Reports

AKUMS Stock 12 Month Forecast

Average Price Target

₹680.00

▲(61.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"423":"₹423","552":"₹552","681":"₹681","487.5":"₹487.5","616.5":"₹616.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹680.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹680.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹680.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[423,487.5,552,616.5,681],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,474.25,490.0769230769231,505.90384615384613,521.7307692307693,537.5576923076923,553.3846153846154,569.2115384615385,585.0384615384615,600.8653846153846,616.6923076923076,632.5192307692307,648.3461538461538,664.1730769230769,{"y":680,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,474.25,490.0769230769231,505.90384615384613,521.7307692307693,537.5576923076923,553.3846153846154,569.2115384615385,585.0384615384615,600.8653846153846,616.6923076923076,632.5192307692307,648.3461538461538,664.1730769230769,{"y":680,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,474.25,490.0769230769231,505.90384615384613,521.7307692307693,537.5576923076923,553.3846153846154,569.2115384615385,585.0384615384615,600.8653846153846,616.6923076923076,632.5192307692307,648.3461538461538,664.1730769230769,{"y":680,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":455,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":523.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":568.2,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":574.7,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":514.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":466.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":451.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.25,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":424.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":446.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":474.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >